Macrophages and angiogenesis in rheumatic diseases

Vascular Cell

Volumn 5, Issue 1, 2013, Pages

  Maruotti, Nicola ^a   Annese, Tiziana ^b   Cantatore, Francesco Paolo ^a   Ribatti, Domenico ^b  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Angiogenesis; Arthritis; Connectivities; Macrophage; Vasculitides

Indexed keywords

ANGIOSTATIN; CHEMOKINE RECEPTOR CXCR2; CXCL1 CHEMOKINE; ENDOSTATIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR C; PLATELET DERIVED GROWTH FACTOR D; STROMAL CELL DERIVED FACTOR 1; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; WNT PROTEIN;

ANGIOGENESIS; ANKYLOSING SPONDYLITIS; BASEMENT MEMBRANE; BEHCET DISEASE; BUERGER DISEASE; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; CHURG STRAUSS SYNDROME; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; GIANT CELL ARTERITIS; HUMAN; HYPOXIA; INFLAMMATION; MACROPHAGE; MACROPHAGE ACTIVATION; MICROSCOPIC POLYANGIITIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; OSTEOARTHRITIS; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIATIC ARTHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; WEGENER GRANULOMATOSIS;

EID: 84878373849     PISSN: None     EISSN: 2045824X     Source Type: Journal    
DOI: 10.1186/2045-824X-5-11     Document Type: Review

References (106)

1. The biology of the macrophage. Ross JA, Auger MJ, The macrophage Oxford: Oxford University Press, Nurke B, Lewis CE, 2 2002
2. Trophic macrophages in development and disease. Pollard JW, Nat Rev Immunol 2009 9 259 270 10.1038/nri2528 19282852
3. The role of myeloid cells in the promotion of tumour angiogenesis. Murdoch C, Muthana M, Coffelt SB, Lewis CE, Nat Rev Cancer 2008 8 618 631 10.1038/nrc2444 18633355
4. Macrophage polarization: tumor associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A, Trends Immunol 2002 23 549 555 10.1016/S1471-4906(02)02302-5 12401408
5. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Balkwill F, Charles KA, Mantovani A, Cancer Cell 2005 7 211 217 10.1016/j.ccr.2005.02.013 15766659
6. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Hanahan D, Folkman J, Cell 1996 86 353 364 10.1016/S0092-8674(00) 80108-7 8756718
7. The role of the vascular phase in solid tumor growth: a historical review. Ribatti D, Vacca A, Dammacco F, Neoplasia 1999 1 293 302 10.1038/sj.neo.7900038 10935483
8. Mechanisms of angiogenesis. Risau W, Nature 1997 386 671 674 9109485
9. Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. Patan S, Munn LL, Jain RK, Microvasc Res 1996 51 260 272 10.1006/mvre.1996.0025 8778579
10. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL, Proc Natl Acad Sci USA 2000 97 14608 14613 10.1073/pnas.97.26.14608 11121063
11. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, Trent JM, Meltzer PS, Hendrix MJ, Am J Pathol 1999 155 739 752 10.1016/S0002-9440(10)65173-5 10487832
12. New vessels, new approaches: angiogenesis as a therapeutic target in musculoskeletal disorders. Ballara SC, Miotla JM, Paleolog EM, Int J Exp Pathol 1999 80 235 250 10607014
13. Angiogenesis as an immunopharmacologic target in inflammation and cancer. Bian XW, Chen JH, Jiang XF, Bai JS, Wang QL, Zhang X, Int Immunopharmacol 2004 4 1537 1547 10.1016/j.intimp.2004.07.017 15351323
14. Vascular permeability factor: a tumor derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC, Pan YC, Olander JV, Connolly DT, Stern D, J Exp Med 1990 172 1535 1545 10.1084/jem.172.6.1535 2258694
15. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Melder RJ, Koenig GC, Witwer BP, Safabakhsh N, Munn LL, Jain RK, Nat Med 1996 2 992 997 10.1038/nm0996-992 8782456
16. Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. Buckley CD, Amft N, Bradfield PF, Pilling D, Ross E, Arenzana-Seisdedos F, Amara A, Curnow SJ, Lord JM, Scheel-Toellner D, Salmon M, J Immunol 2000 165 3423 3429 10975862
17. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Buckley CD, Pilling D, Lord JM, Akbar AN, Scheel-Toellner D, Salmon M, Trends Immunol 2001 22 199 204 10.1016/S1471- 4906(01)01863-4 11274925
18. A heparin-binding angiogenic protein-basic fibroblast growth factor-is stored within basement membrane. Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I, Am J Pathol 1988 130 393 400 3277442
19. Macrophages in rheumatoid arthritis. Maruotti N, Cantatore FP, Crivellato E, Vacca A, Ribatti D, Histol Histopathol 2007 22 581 586 17330813
20. Proteinases and matrix degradation. Okada Y, Kelley's Textbook of Rheumatology Philadelphia: Elsevier Saunders, Harris ED Jr, Budd RC, Firestein GS, etal, 7 2005 63 81 23742460
21. Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis. Pakozdi A, Amin MA, Haas CS, Martinez RJ, Haines GK 3rd, Santos LL, Morand EF, David JR, Koch AE, Arthritis Res Ther 2006 8 132 10.1186/ar2021 16872482
22. Wnt/frizzled signaling in the vasculature: new angiogenic factors in sight. Néstor T, Masckauchán H, Kitajewski J, Physiology 2006 21 181 188 10.1152/physiol.00058.2005 16714476
23. Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10. Pereira C, Schaer DJ, Bachli EB, Kurrer MO, Schoedon G, Arterioscler Thromb Vasc Biol 2008 28 504 510 10.1161/ATVBAHA.107.157438 18174455
24. Wnt5a induces endothelial inflammation via beta-catenin-independent signaling. Kim J, Kim DW, Ha Y, Ihm MH, Kim H, Song K, Lee I, J Immunol 2010 185 1274 1282 10.4049/jimmunol.1000181 20554957
25. Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells. Stefater JA 3rd, Lewkowich I, Rao S, Mariggi G, Carpenter AC, Burr AR, Fan J, Ajima R, Molkentin JD, Williams BO, Wills-Karp M, Pollard JW, Yamaguchi T, Ferrara N, Gerhardt H, Lang RA, Nature 2011 474 511 515 10.1038/nature10085 21623369
26. Integration of the beta-catenin-dependent Wnt pathway with integrin signaling through the adaptor molecule Grb2. Crampton SP, Wu B, Park EJ, Kim JH, Solomon C, Waterman ML, Hughes CC, PLoS One 2009 4 7841 10.1371/journal.pone. 0007841 19924227
27. Chemokines and angiogenesis. Szekanecz Z, Koch AE, Curr Opin Rheumatol 2001 13 202 208 10.1097/00002281-200105000-00009 11333349
28. Angiogenesis in rheumatoid arthritis. Szekanecz Z, Gáspár L, Koch AE, Front Biosci 2005 10 1739 1753 10.2741/1657 15769663
29. Chemokines and their receptors in rheumatoid arthritis. Koch AE, Arthritis Rheum 2005 52 710 721 10.1002/art.20932 15751074
30. C-C chemokines-an overview. Taub DD, Chemokines in disease Austin: RG Landes Company, Koch AE, Strieter RM, 1996 27 54
31. C-X-C chemokines-an overview. Walz A, Kunkel SL, Strieter RM, Chemokines in disease Austin: RG Landes Company, Koch AE, Strieter RM, 1996 1 25
32. Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. Koch AE, Kunkel SL, Harlow LA, Mazarakis DD, Haines GK, Burdick MD, Strieter RM, J Clin Invest 1994 94 1012 1018 10.1172/JCI117414 8083342
33. Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. Walz A, Burgener R, Car B, Baggiolini M, Kunkel SL, Strieter RM, J Exp Med 1991 174 1355 1362 10.1084/jem.174.6.1355 1744577
34. Regulation of angiogenesis by the C-X-C chemokines interleukin-8 and epithelial neutrophil activating peptide-78 in the rheumatoid joint. Koch AE, Volin MV, Woods JM, Kunkel SL, Connors MA, Harlow LA, Woodruff DC, Burdick MD, Strieter RM, Arthritis Rheum 2001 44 31 40 10.1002/1529-0131(200101)44:1<31:: AID-ANR5>3.0.CO;2-4 11212173
35. Fractalkine, a novel chemokine in rheumatoid arthritis and rat adjuvant-induced arthritis. Ruth JH, Volin MV, Haines GK III, Woodruff DC, Katschke KJ Jr, Woods JM, Park CC, Morel JC, Koch AE, Arthritis Rheum 2001 44 1568 1581 10.1002/1529-0131(200107)44:7<1568::AID-ART280>3.0.CO;2-1 11465708
36. Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. Volin MV, Woods JM, Amin MA, Connors MA, Harlow LA, Koch AE, Am J Pathol 2001 159 1521 1530 10.1016/S0002-9440(10)62537-0 11583978
37. CC motif chemokine ligand 13 is associated with rheumatoid arthritis pathogenesis. Yamaguchi A, Nozawa K, Fujishiro M, Kawasaki M, Suzuki F, Takamori K, Ogawa H, Takasaki Y, Sekigawa I, Mod Rheumatol in press
38. Antigen-presenting cells. Thomas R, Arend WP, Kelley's Textbook of Rheumatology Philadelphia: Elsevier Saunders, Harris ED Jr, Budd RC, Firestein GS, etal, 7 2005 101 119 23742460
39. Cytokines. McInnes IB, Kelley's Textbook of Rheumatology Philadelphia: Elsevier Saunders, Harris ED Jr, Budd RC, Firestein GS, etal, 7 2005 379 389 23742460
40. Vascular Permeability Factor/Endothelial Growth Factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, Jackman RW, Senger DR, Dvorak HF, Brown LF, J Exp Med 1994 180 341 346 10.1084/jem.180.1. 341 8006592
41. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, D'Amore P, Dana R, Wiegand SJ, Streinlein JW, J Clin Invest 2004 113 1040 1050 15057311
42. Novel expression of vascular endothelial endothelial growth factor (VEGFR)-3 and VEGF-C on corneal dendritic cells. Hamrah P, Chen L, Zhang Q, Dana R, Am J Pathol 2003 163 57 68 10.1016/S0002-9440(10)63630-9 12819011
43. Expression of vascular endothelial endothelial growth factor receptor-3 (VEGFR-3) on monocytic bone marrow-derived cells in the conjunctiva. Hamrah P, Chen L, Cursiefen C, Zhang Q, Joyce NC, Dana R, Exp Eye Res 2004 79 553 561 10.1016/j.exer.2004.06.028 15381039
44. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Chen L, Hamrah P, Cursiefen C, Zhang Q, Pytowski B, Streilein JW, Dana R, Nat Med 2004 10 813 815 10.1038/nm1078 15235599
45. Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Burke B, Giannoudis A, Corke KP, Gill D, Wells M, Ziegler-Heitbroke L, Lewis CE, Am J Pathol 2003 163 1233 1243 10.1016/S0002-9440(10)63483-9 14507633
46. Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Dineen SP, Lynn KD, Holloway SE, Miller AF, Sullivan JP, Shames DS, Beck AW, Barnett CC, Fleming JB, Brekken RA, Cancer Res 2008 68 4340 4346 10.1158/0008-5472.CAN-07-6705 18519694
47. Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/ macrophages. Murakami M, Iwai S, Hiratsuka S, Yamauchi M, Nakamura K, Iwakura Y, Shibuya M, Blood 2006 108 1849 1856 10.1182/blood-2006-04-016030 16709927
48. Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands. Chung ES, Chauhan SK, Jin Y, Nakao S, Hafezi-Moghadam A, van Rooijen N, Zhang Q, Chen L, Dana R, Am J Pathol 2009 175 1984 1992 10.2353/ajpath.2009.080515 19808642
49. Synovial tissue macrophage as a source of the chemotactic cytokine IL-8. Koch AE, Kunkel SL, Burrows JC, Evanoff HL, Haines GK, Pope RM, Strieter RM, J Immunol 1991 147 2187 2195 1918955
50. Relationship between interleukin-8 and neutrophil adhesion molecules in rheumatoid arthritis. De Gendt CM, De Clerck LS, Bridts CH, Van Osselaer N, Stevens WJ, Rheumatol Int 1996 16 169 173 10.1007/BF01419730 8961381
51. IL-17 contributes to angiogenesis in rheumatoid arthritis. Pickens SR, Volin MV, Mandelin AM 2nd, Kolls JK, Pope RM, Shahrara S, J Immunol 2010 184 3233 3241 10.4049/jimmunol.0903271 20173024
52. Interleukin-18 induces monocyte chemotactic protein-1 production in macrophages through the phosphatidylinositol 3-kinase/Akt and MEK/ERK1/2 pathways. Yoo JK, Kwon H, Khil LY, Zhang L, Jun HS, Yoon JW, J Immunol 2005 175 8280 8286 16339568
53. Expression of platelet-derived growth factors C and D in the synovial membrane of patients with rheumatoid arthritis and osteoarthritis. Pohlers D, Huber R, Ukena B, Kinne RW, Arthritis Rheum 2006 54 788 794 10.1002/art.21670 16508943
54. The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. Carmi Y, Voronov E, Dotan S, Lahat N, Rahat MA, Fogel M, Huszar M, White MR, Dinarello CA, Apte RN, J Immunol 2009 183 4705 4714 10.4049/jimmunol.0901511 19752225
55. Hypoxia regulates macrophage functions in inflammation. Murdoch C, Muthana M, Lewis CE, J Immunol 2005 175 6257 6263 16272275
56. Expression of hypoxia-inducible factor 1 alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Hollander AP, Corke KP, Freemont AJ, Lewis CE, Arthritis Rheum 2001 44 1540 1544 10.1002/1529-0131(200107)44:7<1540::AID-ART277>3.0.CO;2- 7 11465705
57. VEGF release is associated with hypoxia in inflammatory arthritis. Taylor PC, Miotla JM, Etherington P, Winlove P, Young Y, Paleolog E, Maini RN, Arthritis Rheum 2000 43 296
58. The role of macrophage migration inhibitory factor in the inflammatory response and rheumatoid arthritis. Santos LL, Morand EF, Wien Med Wochenschr 2006 156 11 18 10.1007/s10354-005-0243-8 16465610
59. Enhanced expression and DNA binding activity of two CCAAT/enhancer- binding protein isoforms, C/EBPbeta and C/EBPdelta, in rheumatoid synovium. Nishioka K, Ohshima S, Umeshita-Sasai M, Yamaguchi N, Mima T, Nomura S, Murata N, Shimizu M, Miyake T, Yoshizaki K, Suemura M, Kishimoto T, Saeki Y, Arthritis Rheum 2000 43 1591 1596 10.1002/1529-0131(200007)43:7<1591::AID-ANR24>3.0. CO;2-9 10902764
60. Signalling networks regulating cyclooxygenase-2. Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN, Int J Biochem Cell Biol 2006 38 1654 1661 10.1016/j.biocel.2006.03.021 16713323
61. Differential role for c-Rel and C/EBPbeta/delta in TLR-mediated induction of proinflammatory cytokines. Lu YC, Kim I, Lye E, Shen F, Suzuki N, Gerondakis S, Akira S, Gaffen SL, Yeh WC, Ohashi PS, J Immunol 2009 182 7212 7221 10.4049/jimmunol.0802971 19454718
62. Function of C/EBPdelta in a regulatory circuit that discriminates between transient and persistent TLR4-induced signals. Litvak V, Ramsey SA, Rust AG, Zak DE, Kennedy KA, Lampano AE, Nykter M, Shmulevich I, Aderem A, Nat Immunol 2009 10 437 443 19270711
63. Role of macrophage CCAAT/enhancer binding protein delta in the pathogenesis of rheumatoid arthritis in collagen-induced arthritic mice. Chang LH, Huang HS, Wu PT, Jou IM, Pan MH, Chang WC, Wang DD, Wang JM, PLoS One 2012 7 45378 10.1371/journal.pone.0045378 23028973
64. TSG-6: a multifunctional protein associated with inflammation. Milner CM, Day AJ, J Cell Sci 2003 116 1863 1873 10.1242/jcs.00407 12692188
65. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q, Richmond A, Strieter R, Dey SK, DuBois RN, J Exp Med 2006 203 941 951 10.1084/jem.20052124 16567391
66. TSG-6: a pluripotent inflammatory mediator? Milner CM, Higman VA, Day AJ, Biochem Soc Trans 2006 34 446 450 10.1042/BST0340446 16709183
67. Cartilage-specific constitutive expression of TSG-6 protein (product of tumor necrosis factor alpha-stimulated gene 6) provides a chondroprotective, but not antiinflammatory, effect in antigen-induced arthritis. Glant TT, Kamath RV, Bárdos T, Gál I, Szántó S, Murad YM, Sandy JD, Mort JS, Roughley PJ, Mikecz K, Arthritis Rheum 2002 46 2207 2218 10.1002/art.10555 12209527
68. TSG-6: an IL-1/TNF-inducible protein with anti-inflammatory activity. Wisniewski HG, Vilcek J, Cytokine Growth Factor Rev 1997 8 143 156 10.1016/S1359-6101(97)00008-7 9244409
69. Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis. Park YW, Kang YM, Butterfield J, Detmar M, Goronzy JJ, Weyand CM, Am J Pathol 2004 165 2087 2098 10.1016/S0002-9440(10) 63259-2 15579451
70. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, Hibbert L, Churakova T, Travis M, Vaisberg E, Blumenschein WM, Mattson JD, Wagner JL, To W, Zurawski S, McClanahan TK, Gorman DM, Bazan JF, de Waal Malefyt R, Rennick D, Kastelein RA, Immunity 2002 16 779 790 10.1016/S1074-7613(02)00324-2 12121660
71. Interleukin 27 attenuates collagen-induced arthritis. Niedbala W, Cai B, Wei X, Patakas A, Leung BP, McInnes IB, Liew FY, Ann Rheum Dis 2008 67 1474 1479 10.1136/ard.2007.083360 18199596
72. Local expression of interleukin-27 ameliorates collagen-induced arthritis. Pickens SR, Chamberlain ND, Volin MV, Mandelin AM 2nd, Agrawal H, Matsui M, Yoshimoto T, Shahrara S, Arthritis Rheum 2011 63 2289 2298 10.1002/art.30324 21384333
73. Inflammation and angiogenesis in osteoarthritis. Haywood L, McWilliams DF, Pearson CI, Gill SE, Ganesan A, Wilson D, Walsh DA, Arthritis Rheum 2003 48 2173 2177 10.1002/art.11094 12905470
74. Osteoarthritis, angiogenesis and inflammation. Bonnet CS, Walsh DA, Rheumatology (Oxford) 2005 44 7 16 10.1093/rheumatology/keh344
75. Mechanism of disease: angiogenesis in inflammatory diseases. Szekanecz Z, Koch AE, Nat Clin Pract Rheumatol 2007 3 635 643 10.1038/ncprheum0647 17968334
76. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Koch AE, Distler O, Arthritis Res Ther 2007 9 3 17767741
77. Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. Bodolay E, Koch AE, Kim J, Szegedi G, Szekanecz Z, J Cell Mol Med 2002 6 357 376 10.1111/j.1582-4934.2002.tb00514.x 12417052
78. Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis. Cid MC, Hernández-Rodríguez J, Esteban MJ, Cebrián M, Gho YS, Font C, Urbano-Márquez A, Grau JM, Kleinman HK, Circulation 2002 106 1664 1671 10.1161/01.CIR.0000030185.67510.C0 12270860
79. Circulating soluble adhesion molecules in patients with giant cell arteritis. Correlation between soluble intercellular adhesion molecule-1 (sICAM-1) concentrations and disease activity. Coll-Vinent B, Vilardell C, Font C, Oristrell J, Hernández-Rodríguez J, Yagüe J, Urbano-Márquez A, Grau JM, Cid MC, Ann Rheum Dis 1999 58 189 192 10.1136/ard.58.3.189 10364919
80. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Hernández-Rodríguez J, García- Martínez A, Casademont J, Filella X, Esteban MJ, López-Soto A, Fernández-Solà J, Urbano-Márquez A, Grau JM, Cid MC, Arthritis Rheum 2002 47 29 35 10.1002/art1.10161 11932875
81. Disease patterns and tissue cytokine profiles in giant cell arteritis. Weyand CM, Tetzlaff N, Bjornsson J, Brack A, Younge B, Goronzy JJ, Arthritis Rheum 1997 40 19 26 10.1002/art.1780400105 9008596
82. Histopathologic specificity of systemic vasculitis. Lie JT, Rheum Dis Clin North Am 1995 21 883 909 8592742
83. Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis. Weyand CM, Wagner AD, Bjornsson J, Goronzy JJ, J Clin Invest 1996 98 1642 1649 10.1172/JCI118959 8833914
84. Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Nikkari ST, Hoyhtya M, Isola J, Nikkari T, Am J Pathol 1996 149 1427 1433 8909231
85. Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Kaiser M, Weyand CM, Bjornsson J, Goronzy JJ, Arthritis Rheum 1998 41 623 633 10.1002/1529-0131(199804)41:4<623::AID- ART9>3.0.CO;2-6 9550471
86. Expression of ICAM-1, VCAM-1, E-selectin and TNF-alpha on the endothelium of femoral and iliac arteries in thromboangiitis obliterans. Halacheva K, Gulubova MV, Manolova I, Petkov D, Acta Histochem 2002 104 177 184 10.1078/0065-1281-00621 12086338
87. Vascular endothelial growth factor in acute Kawasaki disease. Terai M, Yasukawa K, Narumoto S, Tateno S, Oana S, Kohno Y, Am J Cardiol 1999 83 337 339 10.1016/S0002-9149(98)00864-9 10072219
88. Association of vascular endothelial growth factor gene polymorphisms with Behcet disease in a Korean population. Nam EJ, Han SW, Kim SU, Cho JH, Sa KH, Lee WK, Park JY, Kang YM, Hum Immunol 2005 66 1068 1073 10.1016/j.humimm.2005. 08.238 16386649
89. Vascular endothelial growth factor and monocyte chemoattractant protein-1 in BD patients with venous thrombosis. Bozoglu E, Dinc A, Erdem H, Pay S, Simsek I, Kocar IH, Clin Exp Rheumatol 2005 23 42 S48 16273763
90. Different ELR (+) angiogenic CXC chemokine profiles in synovial fluid of patients with BD, familiar Mediterranean fever, rheumatoid arthritis, and osteoarthritis. Erdem H, Pay S, Serdar M, Simşek I, Dinç A, Muşabak U, Pekel A, Turan M, Rheumatol Int 2005 26 162 167 10.1007/s00296-004-0524-3 15672235
91. Expressions of vascular endothelial growth factor and CD34 in oral aphthous lesions of Behcet's disease. Yacin B, Arda N, Tezel GG, Erman M, Alli N, Anal Quant Cytol Histol 2006 28 303 306 17220143
92. Pretreatment macrophage infiltration of the synovium predicts the clinical effect of both radiation synovectomy and intra-articular glucocorticoids. Jahangier ZN, Jacobs JW, Kraan MC, Wenting MJ, Smeets TJ, Bijlsma JW, Lafeber FP, Tak PP, Ann Rheum Dis 2006 65 1286 1292 10.1136/ard.2005.042333 16627543
93. Chloroquin inhibits production of TNFalpha, interleukin-1 and interleukin-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Jang CH, Choi JH, Byun MS, Jue DM, Rheumatology 2006 45 703 710 10.1093/rheumatology/kei282 16418198
94. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy. Goedkoop AY, Kraan MC, Picavet DI, de Rie MA, Teunissen MB, Bos JD, Tak PP, Arthritis Res Ther 2004 6 326 R334 10.1186/ar1182 15225368
95. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, Nishimoto N, Arthritis Rheum 2003 48 1521 1529 10.1002/art.11143 12794819
96. Chemokines in rheumatic diseases. Szekanecz Z, Szücs G, Szántó S, Koch AE, Curr Drug Target 2006 7 91 102 10.2174/138945006775270231
97. Therapeutic inhibition of leukocyte recruitment in inflammatory diseases. Szekanecz Z, Koch AE, Curr Opin Pharmacol 2004 4 423 428 10.1016/j.coph.2004. 03.013 15251139
98. Vascular involvement in rheumatic diseases: 'vascular rheumatology'. Szekanecz Z, Koch AE, Arthritis Res Ther 2008 10 224 10.1186/ar2515 18947376
99. Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo. Amat M, Benjamim CF, Williams LM, Prats N, Terricabras E, Beleta J, Kunkel SL, Godessart N, Br J Pharmacol 2006 149 666 675 10.1038/sj.bjp.0706912 17016504
100. Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Haringman JJ, Kraan MC, Smeets TJM, Zwinderman KH, Tak PP, Ann Rheum Dis 2003 62 715 721 10.1136/ard.62.8.715 12860725
101. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. Paniagua RT, Sharpe O, Ho PP, Chan SM, Chang A, Higgins JP, Tomooka BH, Thomas FM, Song JJ, Goodman SB, Lee DM, Genovese MC, Utz PJ, Steinman L, Robinson WH, J Clin Invest 2006 116 2633 2642 16981009
102. Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). Ando W, Hashimoto J, Nampei A, Tsuboi H, Tateishi K, Ono T, Nakamura N, Ochi T, Yoshikawa H, J Bone Miner Metab 2006 24 274 282 10.1007/s00774-006-0684-1 16816921
103. Inhibition of macrophage activation and phagocytosis by a novel NF-kB inhibitor, dehydroxymethylepoxyquinomicin. Suzuki E, Umezawa K, Biomed Pharmacother 2006 60 578 586 10.1016/j.biopha.2006.07.089 16978829
104. Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Lainer-Carr D, Brahn E, Nat Clin Pract Rheumatol 2007 3 434 442 17664950
105. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, Park JW, J Natl Cancer Inst 2003 95 516 525 10.1093/jnci/95.7.516 12671019
106. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P, Cancer Cell 2003 3 363 375 10.1016/S1535-6108(03)00077-1 12726862